Journal of Clinical and Aesthetic Dermatology

Plaque-type Psoriasis Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/691107

Contents of this Issue

Navigation

Page 5 of 15

S6 SUPPLEMENT TO THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY [JUNE 2016 • VOLUME 9 • NUMBER 6 • SUPPLEMENT 1] 3. Farber EM. History of the treatment of psoriasis. J Am Acad Dermatol. 1992;27(4):640–645. 4 . Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1–70. 5. Adami S, Cavani A, Rossi F, et al. The role of interleukin-17A in psoriatic disease. BioDrugs. 2014;28:487–497. 6. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011;4(9): 22–42. 7 . Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255. 8. Harder J, Schröder JM, Gläser R. The skin surface as an antimicrobial barrier: present concepts and future outlooks. Exp Dermatol. 2013;22:1–5. 9. Bata-Csorgo Z, Szell M. The psoriatic keratinocytes. Expert Rev Dermatol. 2012;7:473–481. 10. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500. 11. Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol. 2010;10:1325–1334. 12. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007;299:359–366. 13. Martin DA, Towne JE, Kricorian G, et al. The emerging role of interleukin 17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133:17–26. 14. Maddur MS, Miossec P, Kaveri SV, et al. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181:8–18. 15. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567. 16. Blauvelt A, Lebwohl MG, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8): 1946–1953 17. Blauvelt A et al. Updates on psoriasis and cutaneous oncology. In: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013;6(Suppl):S9–S20. 18. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol. 1998;16(3–4):365–396. 19. Goodman WA, Cooper KD, McCormick TS, et al. Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol. 2012;32:65–79. 20. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490–500. 21. Theoharides TC et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21–33. 22. Clark RA, Kupper TS. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Investig. 2006;116:2084–2087. 23. Lowes MA, Bowcock AM, Krueger JG, et al. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873. 24. Ghadially R, Reed JT, Elias PM. Stratum corneum structure and function correlates with phenotype in psoriasis. J Clin Investig. 1996;107(4):558–564. 25. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. 2 6. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383. 27. Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143: 1559–1565. 28. Tsoi LC, Spain SL, Knight J, et al. Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–1348. 2 9. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007;299:359–366. 30. Piskin G et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–1915. 31. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–1211. 32. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687. 33. Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181. 34. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993–1005. 35. Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611–621. 36. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT). Arch Dermatol. 2011;147(9):1031–1039. 37. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12): 2667–2676. 38. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and age- related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. 39. Psoriasis. National Psoriasis Foundation Website. http://www. psoriasis.org. Accessed January 31, 2016. 40. Chen Y, Jiang T, Chen P, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatry Res. 2011;188(2):224–230. 41. Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7(12):e52935. 42. Augustin M, Abeysinghe S, Mallya U, et al. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response—results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2015 Dec 10. [Epub ahead of print].

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Plaque-type Psoriasis Supplement 2016